Findings suggest this method could provide data about tumors sooner than MRIs alone.
The trial advances basic science research on the relationship between purine levels and treatment resistance to develop new treatment options for patients.
Researchers discover how a gene mutation in the cancerous tumor leads to cell cycle dysregulation and heightened sensitivity to a class of inhibitors.
Inhibition of STAT3 signaling may improve survival in those with H3.3G34R/V mutant gliomas, animal studies suggest.
In cell and mouse models, metformin suppressed tumor growth in group A posterior fossa ependymomas.
A common mutation in gliomas sensitizes them to immunotherapy, a finding which researchers believe could have broader therapeutic implications for all glioma patients.